• Volcani International Partnerships

Processa Pharmaceuticals Will Evaluate HT-100 as Treatment for IPF, Other Fibrotic Diseases

HT 100, an anti-inflammatory compound discovered by Mark Pines at the Volcani Institute, will be further developed by Processa Pharmaceuticals.


https://pulmonaryfibrosisnews.com/2019/09/06/processa-will-evaluate-ht-100-treatment-ipf-other-fibrotic-diseases/?fbclid=IwAR0nUF7uahOTbI3VHF2rYIrAj0PYIK91swR6L6w4JDvBsA7yxJVuOueRRcQ



0 views0 comments